Cargando…

Overview of triple negative breast cancer prognostic signatures in the context of data science-driven clinico-genomics research

Detalles Bibliográficos
Autor principal:	Capobianco, Enrico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843365/ https://www.ncbi.nlm.nih.gov/pubmed/36660729 http://dx.doi.org/10.21037/atm-22-5477

Ejemplares similares

Identification of a novel signature with prognostic value in triple-negative breast cancer through clinico-transcriptomic analysis
por: Chen, Chao, et al.
Publicado: (2022)

Triple Negative Breast Cancer – An Overview
por: Aysola, Kartik, et al.
Publicado: (2013)

Data-driven clinical decision processes: it’s time
por: Capobianco, Enrico
Publicado: (2019)

Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer
por: Ding, Ran, et al.
Publicado: (2023)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Autophagy-related prognostic signature for survival prediction of triple negative breast cancer
por: Yang, Qiong, et al.
Publicado: (2022)

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

Stratifying the stratifiers of triple negative breast cancer
por: Wang, Dong-Yu, et al.
Publicado: (2020)

Repurposing of drugs for triple negative breast cancer: an overview
por: Spini, Andrea, et al.
Publicado: (2020)

Tumor microenvironment characterization in triple-negative breast cancer identifies prognostic gene signature
por: Qin, Yan, et al.
Publicado: (2021)

Clinico-pathological and prognostic overview of metastasizing ameloblastoma: An overview of the systematic reviews
por: Sarode, Gargi, et al.
Publicado: (2023)

Triple negative breast cancer: A continuing challenge
por: Gupta, Sudeep
Publicado: (2013)

Targeting MYC for triple-negative breast cancer treatment
por: Klauber-DeMore, Nancy, et al.
Publicado: (2018)

Comparison of Clinico-Pathological Presentations of Triple-Negative versus Triple-Positive and HER2 Iraqi Breast Cancer Patients
por: Alwan, Nada A. S., et al.
Publicado: (2019)

Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures
por: Karn, Thomas, et al.
Publicado: (2011)

A Prognostic Gene Signature for Metastasis-Free Survival of Triple Negative Breast Cancer Patients
por: Lee, UnJin, et al.
Publicado: (2013)

Identification of a DNA Methylation-Based Prognostic Signature for Patients with Triple-Negative Breast Cancer
por: Gao, Yinqi, et al.
Publicado: (2021)

Overview of recent advances in metastatic triple negative breast cancer
por: O'Reilly, David, et al.
Publicado: (2021)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Stratifying triple-negative breast cancer: which definition(s) to use?
por: Adamo, Barbara, et al.
Publicado: (2011)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease
por: Pinto, Joseph A, et al.
Publicado: (2016)

Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer
por: Giró-Perafita, Ariadna, et al.
Publicado: (2017)

Clinico-pathological relationship between androgen receptor and tumour infiltrating lymphocytes in triple negative breast cancer
por: Elghazawy, Hagar, et al.
Publicado: (2021)

Distinct microbiological signatures associated with triple negative breast cancer
por: Banerjee, Sagarika, et al.
Publicado: (2015)

Triple negative breast cancer – prognostic factors and survival
por: Ovcaricek, Tanja, et al.
Publicado: (2010)

Prognostic values of EDNRB in triple-negative breast cancer
por: Liu, Shaoqing, et al.
Publicado: (2020)

An overview of blockchain science and engineering
por: Karame, Ghassan, et al.
Publicado: (2020)

A plasma protein derived TGFβ signature is a prognostic indicator in triple negative breast cancer
por: Katayama, Hiroyuki, et al.
Publicado: (2019)

Identification of the pyroptosis-related prognostic gene signature and characterization of tumor microenvironment infiltration in triple-negative breast cancer
por: Liu, Ji, et al.
Publicado: (2022)

Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer
por: Han, Yiqun, et al.
Publicado: (2023)

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
por: Rhee, Jiyoung, et al.
Publicado: (2008)

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients
por: Bottai, Giulia, et al.
Publicado: (2016)

Large miRNA survival analysis reveals a prognostic four-biomarker signature for triple negative breast cancer
por: Andrade, Fernando, et al.
Publicado: (2020)

Endocan as a prognostic biomarker of triple-negative breast cancer
por: Sagara, Atsunobu, et al.
Publicado: (2016)

Exploring specific prognostic biomarkers in triple-negative breast cancer
por: Bao, Chang, et al.
Publicado: (2019)

Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology
por: Vidula, Neelima, et al.
Publicado: (2017)

Towards AI-driven longevity research: An overview
por: Marino, Nicola, et al.
Publicado: (2023)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rsbrsum34b8rvhh9ktlgb0l70n